Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Scott Eliasof, Ph.D VP of Research at Cerulean presents at Molecular Targets press briefingBoston – at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference today we heard about CRLX101 (Cerulean Pharmaceuticals), a nanopharmaceutical in phase 2 development. The presentation highlighted the challenges and opportunities in cancer drug development.

This post is not intended to be a detailed review of the preclinical data presented, but offers a summary of the value proposition, the intended target and the insights we took away from a press briefing at the conference.

Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

Posted by 

2 Responses to “Cerulean CRLX101 Challenges and Opportunities”

  1. AmandaT

    Couldn’t agree more… HIF is not a proven target and thus far nothing targeting HIF has made it beyond very early clinical. Yes, there is a rationale in RCC but no, there is no clinical evidence. Further to muddy the waters this apparently is also a camptothecin topo-I inhibitor so even a successful result wouldn’t be PoC for HIF. I would love to be proved wrong but I wish VC analysts would make better choices both for their company’s sake and for the sake of the patients who take part in trials.

    • maverickny

      I couldn’t agree more with your well argued sentiments, Amanda. This one seemed a bit of a wild shot, frankly.

Comments are closed.

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!